Numinus Wellness Inc. (OTCMKTS:LKYSF) has entered a collaboration agreement with the Multidisciplinary Association for Psychedelic Studies’ (MAPS) wholly-owned subsidiary, Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC).
Numinus to conduct the compassionate MDMA-assisted psychotherapy study
The collaboration seeks approval for MDMA-assisted posttraumatic stress disorder psychotherapy through an open-label, single-arm compassionate access study. This study will be the first of its kind in Canada which is a massive step in enhancing the accessibility of MDMA-assisted therapy options for individuals with PTSD globally. MAPS and MAPS PBC completed six Phase 2 studies and through the ongoing phase, 3 studies will have undertaken massive steps in showing that MDMA-assisted psychotherapy can offer sufficient benefit to PTSD patients. Recently MDMA-assisted psychotherapy received Breakthrough Therapy designation from the FDA and the studies will support MDMA’s approval.
Numinus’ Vancouver clinic will conduct the compassionate access study once approved. The trial will provide MDMA-assisted psychotherapy to around 20 PTSD patients and collect safety data and outcomes for Health Canada. Most importantly, Numinus therapists, physicians, and staff will receive training on treatment delivery under the MAPS PTSD treatment protocol before Health Canada’s approval.
Dr. Devon Christie, Niminus Medical Director said that they are delighted to collaborate with MAPS to leverage its evidence-based treatment protocol. She added that the company’s clinical infrastructure will make MDMA-assisted psychotherapy accessible in Canada. Christie is a MAPS-trained therapist for MDMA-assisted psychotherapy delivery.
Expanding on MDMA-assisted psychotherapy program
MAPS PBC CEO, Amy Emerson said that training Numinus therapists to deliver the MDMA-assisted therapy for PTSD will offer significant access expansion to the research program for PTSD treatment. Amy said that the psychotherapy is still investigational but once approved the collaboration with Numinus will boost the company’s shared goal of addressing the growing need for proven therapies for PTSD patients.
According to Numinus CEO, Payton Nyquvest, the collaboration with MAPS will deliver a framework for supporting people experiencing PTSD. He said that Numinus aims at expanding patient access to psychedelic psychotherapies and they are delighted to collaborate with MAPS.
